01.05.2014 | Poster presentation | Sonderheft 1/2014 Open Access

Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results
- Zeitschrift:
- Journal of Translational Medicine > Sonderheft 1/2014